
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : $86.5 million
Deal Type : Licensing Agreement
Luxna Announces Technology License Agreement With Takeda
Details : Under the license agreement, Takeda will have the exclusive right to develop and commercialize nucleic acidbased therapies using Luxna XNAs Technology for specified targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 24, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : $86.5 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Aligos Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aligos Therapeutics Expands Existing License Agreement with Luxna Biotech Inc
Details : The amended agreement grants Aligos exclusive rights to use Luxna’s technology to target the genomes of certain families of respiratory viruses, including Coronaviridae, which includes SARS-CoV-2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 15, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Aligos Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Undisclosed
Sponsor : Summit Pharmaceuticals Europe Srl
Deal Size : Undisclosed
Deal Type : Financing
Details : Luxna Biotech will use this capital to drive collaboration with pharmaceutical companies and academia by strengthening its platform technologies for oligonucleotide therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Sponsor : Summit Pharmaceuticals Europe Srl
Deal Size : Undisclosed
Deal Type : Financing
